GST Rate Revisions and Weak US Generics Weigh on Pharma Q2 FY26 Performance

Last updated: 20 October 2025

India's pharmaceutical sector is expected to post moderate growth in the second quarter (Q2) of FY 2025-26, as the industry navigates a complex mix of domestic tax adjustments, global pricing pressures, and selective product gains. While new product launches and steady biosimilar sales offer some re

You have reached daily limit of 2 Free News. To view this or other News please subscribe to CCI PRO :

GST Plus

Stay updated! Stay ads free

Browse CAclubindia ads free.
Latest updates on WA.
Daily E-Newsletter and much more.

CCI PRO annual subscription :

Original Price : INR 2999/-

Offer Price : INR 1999/-

Duration : 1 year
(Prices Inclusive of GST)


Know More

Note: If you are a PRO member already, please click here to login (for ad free experience)

CCI Pro

Category GST   Report

Comment   Share
  303 Views
Comments

Recent News :

  1. GSTN to Bar Filing of Pending GST Returns Older Than 3 Years from 1st December 2025
  2. CBDT Extends ITR and Audit Report Due Dates for AY 2025-26
  3. Fake Income Tax Officer Nabbed: 12th-Pass Man Duped 35 Aspirants with False Job Promises
  4. Bombay High Court Quashes Income Tax Assessment Based on AI-Generated Case Laws
  5. Punjab & Haryana High Court Warns CBDT of Contempt for Delay in Extending ITR Deadline for Audited Cases
  6. GST Cuts to Boost Domestic Demand, Says Finance Ministry's Economic Review for September
  7. CBIC Issues Circular Defining Proper Officers and Monetary Limits under GST Provisions
  8. CBIC Issues FAQs On New Consolidated Customs Notification Effective from November 1, 2025
  9. CBDT Empowers Commissioner, CPC Bengaluru to Rectify and Issue Demands for Certain Income Tax Cases
  10. Finance Ministry Notifies Banking Companies (Nomination) Rules, 2025

More »


Popular News




CCI Pro
Meet our CAclubindia PRO Members
Subscribe Now

Trending Online Classes

view all classess

Follow us

Browse by Category